A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL

Clinical trial NCT06966154 · RECRUITING

Trial details

NCT number: NCT06966154
Sponsor: Fudan University
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Natural Killer/T-cell Lymphoma Relapsed or Refractory Lymphoma Including ENKL

Start date: 2025-05-26
Primary completion: 2027-05-30
Enrollment: 68

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.